Cadrenal Therapeutics (CVKD) narrows losses but warns cash only funds into Q1 2027
Rhea-AI Filing Summary
Cadrenal Therapeutics, Inc. reported second quarter 2026 results and outlined progress in its Cardiac Acute Critical Care Franchise and strategic partnering efforts. For the quarter ended June 30, 2026, the company recorded a net loss of $3.3 million on total operating expenses of $3.3 million, both slightly improved versus 2025.
For the six months ended June 30, 2026, total operating expenses were $5.9 million compared with $7.7 million a year earlier, and the net loss narrowed to $5.8 million from $7.5 million, reflecting lower research and development spending. As of early August 2026, Cadrenal held approximately $4.2 million in cash and cash equivalents and expects its resources to fund operations through the first quarter of 2027.
The company states that existing cash resources are not sufficient to advance product candidates to clinical trial readiness or to commence and complete clinical trials and that it does not plan to start a trial unless funding sufficient to complete that trial is secured, potentially via partnerships, out-licensing, grants, or financings.
Positive
- Operating expenses and net loss decreased materially on a year-to-date basis, with total operating expenses falling to $5.9 million from $7.7 million and net loss narrowing to $5.8 million from $7.5 million for the six months ended June 30.
- Balance sheet strengthened with total stockholders’ equity increasing to $4.1 million at June 30, 2026 from $2.7 million at December 31, 2025, supported by higher additional paid-in capital.
- The company highlights a warrant package that could generate up to $5.8 million in gross proceeds if fully exercised, which would provide additional non-operating funding capacity.
Negative
- Liquidity remains constrained: as of early August 2026, cash and cash equivalents were about $4.2 million, and the company expects its resources to fund operations only through the first quarter of 2027.
- Cadrenal discloses that its existing cash resources are not sufficient to advance product candidates to clinical trial readiness or to commence and complete any clinical trials, making progress dependent on securing additional capital.
- The business continues to generate no product revenue and reported a net loss of $3.3 million for the quarter and $5.8 million for the first half of 2026, underscoring ongoing cash burn.
Filing Explained
The filing reports 3,098,592 shares and $2,388,135 cash at June 30; up to $5.8 million in warrant proceeds remained conditional.
This Form 8-K reports Cadrenal Therapeutics' second-quarter 2026 results and corporate update, with the quarter ended
Its balance sheet lists
The release says potential warrant exercise could generate
A subsequent balance-sheet update should be checked for changes to the warrant receivable and the issued-and-outstanding common-share count.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Q2 2026 Net Loss: $3,322,565
H1 2026 Net Loss: $5,819,105
Q2 2026 Total Operating Expenses: $3,340,400
+5 more
8 metrics
Q2 2026 Net Loss
$3,322,565
Net loss and comprehensive loss for the quarter ended June 30, 2026
H1 2026 Net Loss
$5,819,105
Net loss and comprehensive loss for the six months ended June 30, 2026
Q2 2026 Total Operating Expenses
$3,340,400
Total operating expenses for the quarter ended June 30, 2026
H1 2026 Total Operating Expenses
$5,854,778
Total operating expenses for the six months ended June 30, 2026
Cash and Cash Equivalents 6/30/2026
$2,388,135
Cash and cash equivalents on the balance sheet as of June 30, 2026
Cash Early August 2026
$4,200,000
Approximate cash and cash equivalents as of early August 2026
Stockholders’ Equity 6/30/2026
$4,091,708
Total stockholders’ equity as of June 30, 2026
Potential Warrant Proceeds
$5,800,000
Potential gross proceeds from exercise of warrants issued in the private placement
Key Terms
Orphan Drug Designation, Fast Track designation, Rare Pediatric Disease Designation, Cardiac Surgery-Associated Acute Kidney Injury, +2 more
6 terms
Orphan Drug Designation regulatory
"CAD-1005 has an Orphan Drug Designation (“ODD”) from the U.S. Food and Drug Administration"
Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.
Fast Track designation regulatory
"CAD-1005 has ... FDA Fast Track designation for the treatment and prevention of HIT"
Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.
Rare Pediatric Disease Designation regulatory
"The Company recently submitted a request for Rare Pediatric Disease Designation (RPDD) to the FDA"
A rare pediatric disease designation is an official regulatory status given to a drug or therapy that targets a serious or life‑threatening condition primarily affecting children and is uncommon in the population. It matters to investors because the status often brings financial and development perks — such as tax credits, reduced fees, faster review and periods of market protection — which can lower costs, speed approval and improve the commercial outlook; think of it as a VIP pass that makes bringing a scarce, child‑focused treatment to market easier and potentially more profitable.
Cardiac Surgery-Associated Acute Kidney Injury medical
"CAD-1005 is a novel investigational therapeutic in development for ... Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI)"
Acute kidney injury that occurs after heart surgery, where the kidneys suddenly lose some filtering ability because of reduced blood flow, inflammation, or stress from the operation and recovery. Like a home water filter that clogs after heavy use, this condition is detected by rising waste levels in the blood or falling urine output and matters to investors because it can drive longer hospital stays, higher treatment costs, regulatory scrutiny of therapies and devices, and measurable impacts on healthcare and company financial results.
heparin-induced thrombocytopenia medical
"CAD-1005 is ... in development for the treatment of heparin-induced thrombocytopenia (HIT)"
An immune reaction to the blood-thinning drug heparin that destroys or disables platelets, the blood cells that stop bleeding, while paradoxically increasing the risk of dangerous clots. Think of it as the body’s security system misidentifying helpful staff and triggering chaos that both lowers protection and creates blockages. Investors care because it can change demand for drugs and devices, drive safety warnings or lawsuits, and affect hospital treatment costs and clinical trial outcomes.
Cardiac Acute Critical Care Franchise technical
"portfolio progress across its Cardiac Acute Critical Care Franchise"
Earnings Snapshot
Net loss Q2 2026: $3,322,565
quarter and six months ended June 30, 2026
Net loss Q2 2026
$3,322,565
Compared with $3,667,287 for Q2 2025
Net loss H1 2026
$5,819,105
Compared with $7,512,667 for H1 2025
Total operating expenses Q2 2026
$3,340,400
Compared with $3,734,291 for Q2 2025
Total operating expenses H1 2026
$5,854,778
Compared with $7,662,267 for H1 2025
Cash and cash equivalents early August 2026
$4,200,000
Management expects this to fund operations through Q1 2027
FAQ
What were Cadrenal Therapeutics (CVKD) key financial results for Q2 2026?
Cadrenal reported a Q2 2026 net loss of $3.3 million on total operating expenses of $3.3 million. For the first half of 2026, net loss was $5.8 million, down from $7.5 million in the prior-year period, reflecting lower R&D spending.
How much cash does Cadrenal Therapeutics (CVKD) have and what is its runway?
As of early August 2026, Cadrenal held approximately $4.2 million in cash and cash equivalents. Based on its current operating plan, the company believes these resources will fund operations through the first quarter of 2027, absent additional financing.
Are current funds sufficient for Cadrenal Therapeutics (CVKD) to run clinical trials?
Cadrenal states that its existing cash resources are not sufficient to advance product candidates to clinical trial readiness or to start and complete any clinical trials. It does not plan to commence a trial without funding sufficient to complete that trial in place.
How did Cadrenal Therapeutics (CVKD) operating expenses change year over year?
For Q2 2026, total operating expenses were $3.3 million versus $3.7 million in Q2 2025. For the first half of 2026, operating expenses were $5.9 million, down from $7.7 million, driven mainly by lower research and development expenses.
What is Cadrenal Therapeutics (CVKD) balance sheet position as of June 30, 2026?
At June 30, 2026, Cadrenal reported total assets of $5.6 million, including $2.4 million in cash and cash equivalents and a $2.7 million receivable from issuance of warrants. Total stockholders’ equity was $4.1 million, with current liabilities of $1.5 million.
What programs and designations support Cadrenal Therapeutics (CVKD) pipeline?
Cadrenal’s pipeline includes CAD-1005, tecarfarin, frunexian, and CAD-2000. CAD-1005 has Orphan Drug and Fast Track designations, while tecarfarin has Orphan Drug and Fast Track designations and a pending Rare Pediatric Disease Designation request for Kawasaki disease.
AI-generated analysis. How Rhea-AI works. Not financial advice.
